ArticleCancer research2010
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.Journal for immunotherapy of cancer · 2018Trial
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- Ethyl pyruvate attenuates cellular adhesion and proliferation of diffuse large B-cell lymphoma by targeting c-Jun.Journal of applied biomedicine · 2024Article
- Synthesis and Biological Evaluation of Novel 2-Amino-1,4-Naphthoquinone Amide-Oxime Derivatives as Potent IDO1/STAT3 Dual Inhibitors with Prospective Antitumor Effects.Molecules (Basel, Switzerland) · 2023Article
- Observational
- Peptide vaccination directed against IDO1-expressing immune cells elicits CD8Journal for immunotherapy of cancer · 2020Article
- Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor.Molecules (Basel, Switzerland) · 2020Article
- Contribution of IDO to human respiratory syncytial virus infection.Journal of leukocyte biology · 2019Review
- Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma.Cell death & disease · 2019Article
- Review
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.Seminars in immunopathology · 2019Review
- Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer.Cell death & disease · 2018Article
- 1-Methyl-D-tryptophan Reduces Tumor CD133Scientific reports · 2018Article
- Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.International review of cell and molecular biology · 2018Review
- Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.The pharmacogenomics journal · 2017Article
- HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.Oncotarget · 2017Article
- IDO1 is an Integral Mediator of Inflammatory Neovascularization.EBioMedicine · 2016Article
- Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.Journal of cancer research and clinical oncology · 2016Review
- Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries.Journal of inflammation (London, England) · 2016Review
- IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.International immunology · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Efforts to improve cancer care in the developing world will benefit from the identification of simple, inexpensive, and broadly applicable medical modalities based on emergent innovations in treatment, such as targeting mechanisms of tumoral immune tolerance. In this report, we offer preclinical evidence that the low-cost, anti-inflammatory agent ethyl pyruvate elicits a potent immune-based antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enzyme for many human tumors. Consistent with its reported ability to interfere with NF-kappaB function, ethyl pyruvate blocks IDO induction both in vitro and in vivo. Antitumor activity was achieved in mice with a noncytotoxic dosing regimen of ethyl pyruvate shown previously to protect against lethality from sepsis. Similar outcomes were obtained with the functional ethyl pyruvate analogue 2-acetamidoacrylate. Ethyl pyruvate was ineffective at suppressing tumor outgrowth in both athymic and Ido1-deficient mice, providing in vivo corroboration of the importance of T-cell-dependent immunity and IDO targeting for ethyl pyruvate to achieve antitumor efficacy. Although ethyl pyruvate has undergone early-phase clinical testing, this was done without consideration of its possible applicability to cancer. Our findings that IDO is effectively blocked by ethyl pyruvate treatment deepen emerging links between IDO and inflammatory processes. Further, these findings rationalize oncologic applications for this agent by providing a compelling basis to reposition ethyl pyruvate as a low-cost immunochemotherapy for clinical evaluation in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.